While Transforming growth factor-βs (Tgf-βs) have been known to play an important role in liver fibrosis through an activation of Hepatic Stellate Cells (HSC), their fibrotic role on hepatocytes in liver damage has not been addressed thoroughly. To shed more light on the hepatocyte-specific role of Tgf-β signaling during liver fibrosis, we generated transgenic mice expressing constitutively active Tgf-β type I receptor Alk5 under the control of albumin promoter. Uninjured mice with increased Tgf-β/Alk5 signaling in hepatocytes (caAlk5/Alb-Cre mice) did not show characteristics related to hepatocyte death, fibrosis and inflammation. When subjected to thioacetamide (TAA) treatment, caAlk5/Alb-Cre mice exhibited more severe liver injury, when compared to control littermates. After TAA administration for 12 weeks, an increase in pathological changes was evident in caAlk5/AlbCre livers, with higher number of infiltrating cells in the portal and periportal area. Immunohistochemistry for F4/80, myeloperoxidase and CD3 showed that there was an increased accumulation of macrophages, neutrophils and T-lymphocytes, respectively, in caAlk5/Alb-Cre livers. Coincidently, we observed an exacerbated liver damage as seen by increases in serum aminotransferase level and number of apoptotic hepatocytes in caAlk5/Alb-Cre mice. Sirius staining of collagen demonstrated that the fibrotic response was worsened in caAlk5/Alb-Cre mice. The enhanced fibrosis in mutant livers was associated with marked production of α-SMA-positive myofibroblast. Hepatic expression of genes indicative of HSC activation was greater in caAlk5/Alb-Cre mice. In conclusion, our data indicated that elevation of Tgf-β signaling via Alk5 in hepatocytes is not sufficient to induce liver pathology but plays an important role in amplifying TAA-induced liver damage.
Introduction
Hepatic injury contributes to the pathogenesis of several liver diseases (Mengshol et al., 2007; Natori et al., 2001) . Following an injury, Hepatic cells that include Hepatocytes, Hepatic Stellate Cells (HSCs), Kupffer cells, and endothelial cells communicate with each other to trigger the healing response which leads to the tissue repair. This cell-to-cell interaction is critical for promoting liver regeneration and maintaining organ function (Diehl, 2012; Forbes and Newsome, 2016; Friedman et al., 2013) . The communication among cells can be achieved by various types of tropic factor, hormone, extracellular matrix (ECM) protein, proteolytic enzyme and extracellular nucleic acid (de Oliveira et al., 2017; Seifert et al., 2015; Tian et al., 2016; Zheng et al., 2016) . Better understanding of how these molecules govern cell behaviors will lead to a new strategy to improve organ repair and reduce the risk of developing liver disease in individual exposed to hepatotoxin.
Transforming growth factor-βs (Tgf-βs) are widely distributed, multifunctional cytokines that are released from compromised epithelial cells and stimulated immune cells during organ injury (Dooley and ten Dijke, 2012; Liu et al., 2006; Meng et al., 2016) . Tgf-β ligands exert their effects via a family of transmembrane serine/threonine kinase receptors, Tgf-β type II receptor TβRII and Tgf-β type I receptor TβRI (Massague, 2012; Shi and Massague, 2003; Weiss and Attisano, 2013) . Upon ligand binding, the TβRII activates the kinase catalytic domain of the TβRI (Alk5 or Alk1), leading to phosphorylation of Smad proteins. While the Alk1 receptor phosphorylates Smad1, Smad5 and Smad8, the Alk5 receptor causes phosphorylation of Smad2 and Smad3 (Massague and Chen, 2000; ten Dijke and Hill, 2004) . The phosphorylated Smad proteins subsequently form a complex with Smad4 and translocate to nucleus to regulate transcription of specific genes (Macias et al., 2015) .
In liver, Tgf-βs are known as a key HSC activator that promotes fibrosis after liver injury (Dooley and ten Dijke, 2012; Fabregat et al., 2016) . Accumulating evidence from studies of genetically engineered mouse models revealed that Tgf-βs also act on hepatocytes to amplify hepatic fibrogenesis. Dooley and coworkers have reported that blunting Tgf-β signaling in hepatocytes with antagonistic Smad7 attenuated carbon tetrachloride (CCl 4 )-induced fibrosis (Dooley et al., 2008) . In line with this observation, Yang et al. have shown that Tgf-β signaling in hepatocytes was essential for the development of spontaneous liver fibrosis in Tak1 knockout mice (Yang et al., 2013) . However, this idea is currently challenged by results from recent work employing mutant mice lacking TβRII in hepatocytes. Mu et al. demonstrated that deletion of TβRII in hepatocytes did not affect the development of liver fibrosis in several mouse models of liver injury (Mu et al., 2016) . In this study, we investigated the role of Tgf-β signaling via Alk5 in hepatocytes during thioacetamide(TAA)-induced injury in mice.
Materials and methods

Experimental mice
Alb-Cre mice were purchased from Jackson laboratories (Bar Harbor, ME). Mice expressing the constitutively active (ca) Alk5 transgene (caAlk5 mice) have been previously described (Bartholin et al., 2008 Genotype of animals was identified by PCR analysis (VioTwinPack PCR kit, Viogene Biotech) on DNA extracted from mouse tail using DirectPCR lysis reagent (Viagen). The following primers were used for PCR reaction: caAlk5, 5′-AGAAAGAACAATCAAGGGTCC-3' and TTGTGAACAGAAGTTAAGGC-3′;
Cre, 5′-AGGTGTAGAGAAGGCACTTAGC-3′ and 5′-CTAATCGCCATCTTC-CAG CAGG-3′. To confirm the Cre-mediated removal of stop sequence from caAlk5 gene, PCR analysis of genomic DNA extracted from mouse liver were performed using the following primers (Vincent et al., 2010) : 5′-GACAG-CAACGGAATTCGATATC-3′ and 5′-CTCTAGAGCCTCTGCTAACC-3′. The caAlk5 mRNA expression was demonstrated by quantitative RT-PCR performed on total RNA from livers of control and caAlk5/Alb-Cre mice. RT-PCR primer set for caAlk5 was previously described (Bartholin et al., 2008) .
Induction liver injury
The protocol for thioacetamide-induced liver damage was adapted from those that previously described (Hayashi and Sakai, 2011) . In brief, adult (8-12 weeks) mice were injected intraperitoneally with TAA (Sigma) at 100 μg/g body weight, three times a week for one week followed by one-week treatment at 150 μg/g body weight. Starting on the third week, mice received three TAA injections (200 μg/g 
Histochemistry and fibrosis quantification
Liver sections were cut to 6 μm and stained with hematoxylin-eosin (Bio-Optica).
To access collagen deposition, sections were stained with Sirius Red (saturated picric acid containing 0.1% direct red and 0.1% Fast green FCF, Sigma). Five Sirius Red-stained slides per mouse were generated, with six 10x pictures taken randomly per slide for a total of 30 images per mouse. The images were analyzed for Sirius Red-positive area using ImageJ program. Five mice per experimental group were used for collagen quantification.
Immunoperoxidase and immunofluorescence staining
For immunohistochemistry, paraffin-embedded, bouin-fixed sections were deparaffinized, rehydrated and boiled in citrate buffer for 15 min. After protein blocking 
RT-PCR analysis
RNA was prepared from snap-frozen tissue using RNeasy mini kit (Qiagen).
QuantiNova RT kit (Qiagen) and Omniscript RT kit (Qiagen) was used to synthesize cDNA from 1 μg of RNA. For RT-PCR reactions, cDNA samples were amplified with Hotstar Taq DNA polymerase (Qiagen). Quantitative RT-PCRs were carried out with Applied Biosystems real-time PCR 7500 using iTaq Universal SYBR green supermix (Bio-Rad Lab). Data were represented as the relative expression of gene after normalizing to β-actin. All primer pairs have been Article No~e00305 previously described (Bartholin et al., 2008; Basciani et al., 2004; Bopp et al., 2013; Puche et al., 2013; Stewart et al., 2014; Xiang et al., 2012; Yang et al., 2013 ).
Statistical analysis
All experiments were performed with five animals per experimental group and representative data were presented as means ± SD. Comparisons were performed by ANOVA test and differences were considered significant if P < 0.05.
Results
Alb-Cre-mediated expression of caAlk5 enhanced Tgf-β signaling in hepatocytes
To study the role of Tgf-β signaling to hepatocytes during liver injury, we generated caAlk5/Alb-Cre mice expressing constitutively active (ca) Alk5 in hepatocytes by crossing Alb-Cre mice with caAlk5 mice. We verified that the AlbCre transgene expression was able to induce Cre-mediated removal of stop sequence upstream of caAlk5 coding sequence in liver parenchyma by using PCR analysis with pCAG/pTβRI primers (Vincent et al., 2010) (Fig. 1A) . The DNA of control mice displayed a 1.93-kb-PCR product amplified from inactive caAlk5 transgene, while DNA from the mutant mice showed a single band of 350-bp-PCR product representing a product of recombined caAlk5 transgene (Fig. 1B) . Quantitative RT-PCR experiments revealed that caAlk5 mRNA was highly expressed in the liver caAlk5/Alb-Cre mice (Fig. 1C) . To demonstrate that expression of caAlk5 could lead to the increased Tgf-β signaling in mutant livers, we performed immunohistochemistry using p-Smad2/3 antibody. The results
showed that a higher number of p-Smad2/3 positive hepatocytes were found in caAlk5/Alb-Cre livers compared to those in control ( Fig. 2A and B) . H&E staining demonstrated comparable hepatic architecture between control and caAlk5/Alb-Cre mice ( Fig. 3A and C) . No sign of liver damage and fibrosis was observed in caAlk5/Alb-Cre mice and control littermates ( Fig. 3B and D) . These findings indicated that expression of caAlk5 in hepatocytes is not sufficient to induced liver damage in mice. Fig. 4M-P ). In addition, severe swelling of hepatocytes was noticeable in livers of caAlk5/Alb-Cre mice (Fig. 4P) , whereas less swollen hepatocytes were noted in liver of control mice (Fig. 4L ). These data suggested that hepatocyte degeneration was more pronounced in mutants than those in control mice after TAA treatment.
[ ( F i g . _ 2 ) T D $ F I G ] Because TAA treatment lead to an increased number of cells that exhibited inflammatory cell appearance (Fig. 4) , we next performed immunostaining to determine whether which type of inflammatory cells are increased in mutant liver after TAA exposure. F4/80 immunohistochemistry revealed an increased number of Kupffer cells/macrophages in liver of caAlk5/Alb-Cre mice treated with TAA (Fig. 5A , B and C). Similarly, immunochemistry for neutrophil marker myeloperoxidase showed that more neutrophils were accumulated in caAlk5/ Alb-Cre liver (Fig. 5D, E and F) . In addition, we assessed T-lymphocyte infiltration into liver by anti-CD3 immunostaining. While some CD3 positivity can be detected in control livers, caAlk5/Alb-Cre mutants displayed an increased amount of CD3-positive cells surrounding hepatic blood vessel (Fig. 5G, H and I ).
Our result suggested that enhanced Tgf-β signaling in hepatocytes promoted recruitment of macrophages, neutrophils and T cell into liver after TAA treatment.
[ ( F i g . _ 3 ) T D $ F I G ] To address the level of tissue injury induced by TAA treatment in control and caAlk5/Alb-Cre mice, serum aminotransferase was quantified. Our results showed that serum Aspartate transaminase (AST) and Alanine transaminase (ALT) were higher in TAA-treated caAlk5/Alb-Cre mice than those in TAA-treated control ( Fig. 6A-B) . Since AST/ALT is also expressed in cells of other organs, such as, heart, skeletal muscle and kidney, damage to these organs can also lead to increased level of serum AST and ALT. To validate whether TAA-induced liver injury is increased in caAlk5/Alb-Cre mice, we performed immunohistochemistry for cleaved-caspase-3 to detect apoptotic cells in liver of TAA-treated mice. The data showed that a higher number of apoptotic hepatocytes were found in livers of caAlk5/Alb-Cre mice compared to those of control (Fig. 7) . These findings suggested that caAlk5/Alb-Cre mice exhibited more severity of hepatic damage than control mice after TAA treatment. 
[ ( F i g . _ 4 ) T D $ F I G ]
caAlk5/Alb-Cre mutants displayed severe liver fibrosis induced by TAA treatment
To determine whether expression of caAlk5 in hepatocytes could affect TAAinduced fibrogenesis, Sirius red/fast green staining was used to assess the degree of liver fibrosis. After TAA exposure for 6 weeks, sparse collagen fibers were detected in livers of control mice (Fig. 8A-B) . The higher quantity of collagen was found in caAlk5/Alb-Cre mice compared with control mice (Fig. 8C, D) . TAA treatment for 12 weeks resulted in widened portal area forming fibrous septa throughout the liver parenchyma of control mice ( Fig. 8E and F) . TAA-treated caAlk5/Alb-Cre mice demonstrated increased portal fibrosis, bridging fibrosis and increased scar thickness than in TAA-treated control mice ( Fig. 8G and H) . There is a significant difference after TAA treatment when compared with genotype-specific saline control (*P < 0.05). There is a significant difference when compared with genotype-specific saline control and between genotypes after TAA treatment (**P < 0.05). Immunochemistry with NovaRed substrate, counterstained with hematoxylin. CV denotes the central vein. PT denotes the portal tract.
[ ( F i g . _ 5 ) T D $ F I G ]
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Striking collagen deposition was observed in the periportal area and fibrous septa of caAlk5/Alb-Cre mice (Fig. 8H) , whereas less Sirius Red-stained collagen fibers were detected in control livers (Fig. 8F ). Morphometric analysis of Sirius redstained sections showed an increase in collagen deposition in caAlk5/Alb-Cre livers after 6-week and 12-week TAA exposure (Fig. 8I) .
[ ( F i g . _ 6 ) T D $ F I G ] There is a significant difference when compared with genotype-specific saline control and between genotypes after TAA treatment (**P < 0.05).
[ ( F i g . _ 7 ) T D $ F I G ] There is a significant difference after TAA treatment when compared with genotypespecific saline control (*P < 0.05). There is a significant difference when compared with genotypespecific saline control and between genotypes after TAA treatment (**P < 0.05). CV denotes the central vein.
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Increased production of myofibroblast caAlk5/Alb-Cre mutants
Collagen and other extracellular matrix proteins in fibrotic livers are mainly produced from myofibroblast. To determine an amount of myofibroblast in livers of TAA-treated mice, we performed anti-α-SMA Immunohistochemistry using α-SMA antibody (Fig. 9) . The result showed that a notable increase of myofibroblasts was observed in liver of TAA-treated caAlk5/Alb-Cre mice (Fig. 9E ). This suggested an involvement of Tgf-β signaling in hepatocytes during myofibroblast production. It is possible that enhanced Tgf-β signaling could stimulate the release of fibrogenic factors from hepatocytes leading to myofibroblast differentiation via HSC activation. To test this idea, quantitative RT-PCR analysis was performed to measure mRNA expression of well-known fibrogenic factors. As shown in Fig. 10 , caAlk5/Alb-Cre displayed an increased expression of these factors such as PDGF-A, PDGF-B or Tgf-β in their livers significantly different compared with saline control for the same genotype. There is a significant difference after TAA treatment when compared with genotype-specific saline control and between genotypes at the same time point (**P < 0.05).
Article No~e00305 compared to those in control livers ( Fig. 10A-C) . Of interest, a hepatocyte-derived CTGF had been implicated in Tgf-β-mediated liver fibrosis; its mRNA expression in mutant liver was also increased (Fig. 10D ).
Discussion
The relationship between Tgf-β signaling and hepatic cell damage has been previously described in many situations (Dooley and ten Dijke, 2012; Liu et al., 2006) . Tgf-β was found to induce cell death by stimulating expression of proteins in apoptotic machinery (Jang et al., 2002; Perlman et al., 2001; Ramesh et al., 2008) . Overexpression of Tgf-β ligand was shown to enhance liver injury in mouse model of alcoholic liver disease (Preisegger et al., 1999) . Inhibition of Tgf-β signaling by over expression of antagonistic Smad7 protected mice against CCl 4 -induced liver injury (Dooley et al., 2008) , whereas abrogation of Smad7 exacerbated CCl 4 -dependent liver injury (Hamzavi et al., 2008) . These findings suggested that Tgf-β signaling promotes hepatic cell injury following experimentally induced liver damage. In this study, we characterized caAlk5/Alb-Cre mice to determine whether elevation of Tgf-β/Alk5 signaling in hepatocytes could lead to spontaneous liver damage. We did not find any histological and biochemical feature of hepatic cell death in the transgenic mice. This observation indicated that activation of Alk5-mediated Tgf-β signaling was not sufficient to cause hepatocellular damage in mice.
[ ( F i g . _ 9 ) T D $ F I G ] genotype. There is a significant difference when compared with genotype-specific saline control and between genotypes after TAA treatment (**P < 0.05). CV denotes the central vein.
Although expression of caAlk5 in hepatocytes did not seem to be enough to cause liver injury, it made liver more susceptible to a toxicological insult. Following TAA treatment, caAlk5/Alb-Cre mice showed a higher level of serum liver enzyme when compared to control littermates. In accordance with this data, a number of apoptotic cells were higher in the liver of transgenic mice. Our data would support the notion that, while augmentation of Tgf-β signaling in hepatocytes does not affect the integrity of cells, hepatocytes with increased Tgf-β/Alk5 signaling are more prone to chemical-induced cell damage. This reflects cooperation between Tgf-β/Alk5 signaling and other signaling pathways in amplifying liver damage caused by toxic stimuli. Further studies are necessary to identify a liver-damaging factor that may act synergistically with Tgf-β to promote liver injury.
[ ( F i g . _ 1 0 ) T D $ F I G ] for the analysis. There is a significant change in gene expression when compared with genotype-specific saline control (*P < 0.05). There is a significant difference when compared with genotype-specific saline control and between genotypes after TAA treatment (**P < 0.05).
In the past years, some efforts have been made to identify the role of hepatocytedependent Tgf-β signaling in the fibrotic liver response (Dooley et al., 2008; Mu et al., 2016; Yang et al., 2013) . Yang et al. reported that ablation of TβRII in hepatocytes decreased spontaneous liver fibrosis developed in Tak knockout mice (Yang et al., 2013) . This suggested that TβRII-dependent signaling in hepatocytes was essential for the progression of hepatic fibrosis. A recent study by Mu and coworkers, however demonstrated that the deletion of TβRII in hepatocytes did not affect the development of CCl 4 -induced fibrosis (Mu et al., 2016) , indicating that epithelial Tgf-β signaling did not contribute to liver fibrogenesis. Our results showed that expression of caAlk5 in hepatocytes led to increased myofibroblasts production and enhanced interstitial collagen accumulation in liver of caAlk5/AlbCre mice treated with TAA. Concomitantly, there was increased mRNA expression of potent fibrogenic factors such as PDGF-A, PDGF-B and Tgf-β in mutant liver compared to those in control. Of interest, connective tissue growth factor (CTGF) that was known to be regulated by Tgf-β signaling (Gressner et al., 2007) was also increased in caAlk5/Alb-Cre livers. Since previous report indicating that Alk5-dependent Tgf-β signaling mediated the up-regulation of CTGF expression in hepatocytes (Weng et al., 2007) , we speculate that increased expression of CTGF in caAlk5/Alb-Cre liver might be, at least, partially responsible for the enhancement of fibrogenesis. While the definite mechanism of how Tgf-β signaling in hepatocytes amplifies fibrosis needs further investigation, results from our study support the view of hepatocyte as an important player in Alk5-mediated fibrogenic response following liver injury.
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